Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 35

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 35
---
 on the last business day of the Company’s second fiscal quarter, or the Company’s annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of the Company’s voting and non-voting Common Stock held by non-affiliates is less than $700.0 million measured on the last business day of the Company’s second fiscal quarter.

| S-7 |

<div align='center'>THE OFFERING</div>

| Common Stock offered by us                              |     | Shares of our common stock having an aggregate offering price of up to $3,557,000.                                                                                                                                                                                                                                                                             |
| Manner of Offering                                      |     | “At the Market Offering” that may be made from time to time through or to, Maxim, as sales agent or principal. See “Plan of Distribution” on page S-14                                                                                                                                                                                                         |
| Common stock outstanding immediately before offering    |     | 1,796,597 shares of common stock                                                                                                                                                                                                                                                                                                                               |
| Common stock outstanding immediately after offering (1) |     | 2,456,522 shares of common stock assuming 659,925 shares of common stock are sold, based on an assumed offering price of $5.39 per share, which was the closing price of our common stock on the Nasdaq Capital Market on November 5, 2025. The actual number of shares of our common stock issued will vary depending on the sales price under this offering. |
| Use of Proceeds                                         |     | We currently intend to use the net proceeds from this offering for working capital and general corporate purposes. See ‘‘Use of Proceeds” on page S-12 of this prospectus supplement.                                                                                                                                                                          |
| Risk Factors                                            |     | Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-8 of this prospectus supplement for a discussion of factors you should consider carefully when making an investment decision.                                                                                                                               |
| Exchange Listing                                        |     | Our common stock is traded on Nasdaq Capital Market under the symbol “BGLC.”                                                                                                                                                                                                                                                                                   |
| Exclusive Sales Agent                                   |     | Maxim Group LLC is acting as the exclusive sales agent in connection with this offering.                                                                                                                                                                                                                                                                       |
| Transfer Agent                                          |     | The transfer agent and registrar for our common stock is Securities Transfer Corporation. .                                                                                                                                                                                                                                                                    |

| (1) | The number of shares of common stock that will be outstanding after this offering as shown above is based on 1,796,597